Trospium Chloride
Brand Names: Sanctura
Methodology & AI Transparency ⓘ
Trospium Chloride Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Trospium Chloride Tablets are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
- 2 Real-world patient consensus: Zero-PHI community consensus: 77% favorable across 11 logged regimens (Sanctura).
- 3 Typical cash cost range: Dispensing cost comparison spans $9.51 mail/discount cash up to $34.50 uninsured retail (federal NADAC $0.2068).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Trospium Chloride: headache (4.2%), constipation (9.6%), dry mouth (6.9%).
Ask our AI Specialists anything about Trospium Chloride
Trospium Chloride Mechanism, CYP450 Pathways & DailyMed Monograph
Trospium Chloride Tablets are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. Trospium Chloride Tablets are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1 )
12.1 Mechanism of Action Trospium chloride is a muscarinic antagonist. Trospium chloride antagonizes the effect of acetylcholine on muscarinic receptors in cholinergically innervated organs including the bladder. Its parasympatholytic action reduces the tonus of smooth muscle in the bladder. Receptor assays showed that trospium chloride has negligible affinity for nicotinic receptors as compared to muscarinic receptors at concentrations obtained from therapeutic doses.
Following administration (60 mg/1 Capsule, Extended Release), Trospium Chloride achieves ~9.6% systemic bioavailability (Trospium Chloride) bioavailability and peak plasma tmax within 5 to 6 hours (trospium chloride) onset, governed by a Steady-state plasma equilibrium reached over 3–10 hour t½ intervals for Trospium Chloride terminal half-life through predominantly hepatic biotransformation with renal elimination of polar trospium chloride conjugates.
Before initiating Trospium Chloride at 60 mg/1 Capsule, Extended Release, clinical safety checklists rule out angioedema, rash and anaphylactic reaction have been reported.; confirmed ige-mediated allergy or cutaneous reaction to trospium chloride (trospium chloride) components. Logged tolerability patterns center on constipation (9.6% of reports), nausea (8.1% of reports), dry mouth (6.9% of reports).
Monitor serum digoxin concentrations when initiating or adjusting Trospium Chloride due to transporter overlap.
Reconcile eGFR-adjusted medications before escalating Trospium Chloride in polypharmacy regimens.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Angioedema, rash and anaphylactic reaction have been reported.
- Confirmed IgE-mediated allergy or cutaneous reaction to Trospium Chloride (Trospium Chloride) components
Logged Side-Effect Incidence (11 Reports)
Trospium Chloride Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Trospium Chloride)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute: What a 357-Participant Study Found Participants with acute schizophrenia with prespecified impairments demonstrated significant cognitive improvement with xanomeline/trospium compared with placebo. The American journal of psychiatry • 2025-03-01 • Phase III Randomized Trial | N = 357 | 93/100 | PMID 39659157 ↗ |
| New Insights on Long-Term safety and real-world benefits of Xanomeline and Trospium Chloride in: What a 366-Participant Study Found Long-term treatment with X/T over 52 weeks was safe, generally well tolerated, and associated with durable symptom improvement in people with schizophrenia. The American journal of psychiatry • 2026-03-01 • Phase III Randomized Trial | N = 366 | 93/100 | PMID 41634905 ↗ |
Trospium Chloride Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.2068/unit (~$6.20/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $9.51 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 11 Anonymous DotMD Community Micro-Logs | $10.94 / mo | View logs ↓ |
Trospium Chloride Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Trospium Chloride RxNorm Concept ID | 857560 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.2068 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $9.51 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 77.00% Worth It (11 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Trospium Chloride Patient Community, Cohort Filters & Dosage Logs
Cross-verified Trospium Chloride (cholinergic muscarinic antagonist) monograph synthesizing RxNorm 857560, openFDA FAERS signals, and $9.51–$34.50 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Trospium Chloride community threads and patient logs by age, biological sex, dosage, and treatment duration.